Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 315

1.

Signaling networks associated with AKT activation in non-small cell lung cancer (NSCLC): new insights on the role of phosphatydil-inositol-3 kinase.

Scrima M, De Marco C, Fabiani F, Franco R, Pirozzi G, Rocco G, Ravo M, Weisz A, Zoppoli P, Ceccarelli M, Botti G, Malanga D, Viglietto G.

PLoS One. 2012;7(2):e30427. doi: 10.1371/journal.pone.0030427. Epub 2012 Feb 17.

PMID:
22363436
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features.

Trigka EA, Levidou G, Saetta AA, Chatziandreou I, Tomos P, Thalassinos N, Anastasiou N, Spartalis E, Kavantzas N, Patsouris E, Korkolopoulou P.

Oncol Rep. 2013 Aug;30(2):623-36. doi: 10.3892/or.2013.2512. Epub 2013 May 31.

PMID:
23728071
[PubMed - indexed for MEDLINE]
3.

Multiple genetic alterations within the PI3K pathway are responsible for AKT activation in patients with ovarian carcinoma.

De Marco C, Rinaldo N, Bruni P, Malzoni C, Zullo F, Fabiani F, Losito S, Scrima M, Marino FZ, Franco R, Quintiero A, Agosti V, Viglietto G.

PLoS One. 2013;8(2):e55362. doi: 10.1371/journal.pone.0055362. Epub 2013 Feb 7.

PMID:
23408974
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Diverse prognostic roles of Akt isoforms, PTEN and PI3K in tumor epithelial cells and stromal compartment in non-small cell lung cancer.

Al-Saad S, Donnem T, Al-Shibli K, Persson M, Bremnes RM, Busund LT.

Anticancer Res. 2009 Oct;29(10):4175-83.

PMID:
19846969
[PubMed - indexed for MEDLINE]
Free Article
5.

Molecular alterations of Ras-Raf-mitogen-activated protein kinase and phosphatidylinositol 3-kinase-Akt signaling pathways in colorectal cancers from a tertiary hospital at Kuala Lumpur, Malaysia.

Yip WK, Choo CW, Leong VC, Leong PP, Jabar MF, Seow HF.

APMIS. 2013 Oct;121(10):954-66. doi: 10.1111/apm.12152. Epub 2013 Aug 29.

PMID:
23992303
[PubMed - indexed for MEDLINE]
6.

Atorvastatin overcomes gefitinib resistance in KRAS mutant human non-small cell lung carcinoma cells.

Chen J, Bi H, Hou J, Zhang X, Zhang C, Yue L, Wen X, Liu D, Shi H, Yuan J, Liu J, Liu B.

Cell Death Dis. 2013 Sep 26;4:e814. doi: 10.1038/cddis.2013.312.

PMID:
24071646
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Somatic mutations in epidermal growth factor receptor signaling pathway genes in non-small cell lung cancers.

Lee SY, Kim MJ, Jin G, Yoo SS, Park JY, Choi JE, Jeon HS, Cho S, Lee EB, Cha SI, Park TI, Kim CH, Jung TH, Park JY.

J Thorac Oncol. 2010 Nov;5(11):1734-40. doi: 10.1097/JTO.0b013e3181f0beca. Erratum in: J Thorac Oncol. 2011 Jun;6(6):1147.

PMID:
20881644
[PubMed - indexed for MEDLINE]
8.

Ran is a potential therapeutic target for cancer cells with molecular changes associated with activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK pathways.

Yuen HF, Chan KK, Grills C, Murray JT, Platt-Higgins A, Eldin OS, O'Byrne K, Janne P, Fennell DA, Johnston PG, Rudland PS, El-Tanani M.

Clin Cancer Res. 2012 Jan 15;18(2):380-91. doi: 10.1158/1078-0432.CCR-11-2035. Epub 2011 Nov 16.

PMID:
22090358
[PubMed - indexed for MEDLINE]
Free PMC Article
9.
10.

PI3K/PTEN/AKT/mTOR pathway genetic variation predicts toxicity and distant progression in lung cancer patients receiving platinum-based chemotherapy.

Pu X, Hildebrandt MA, Lu C, Lin J, Stewart DJ, Ye Y, Gu J, Spitz MR, Wu X.

Lung Cancer. 2011 Jan;71(1):82-8. doi: 10.1016/j.lungcan.2010.04.008. Epub 2010 May 5.

PMID:
20447721
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

miR-205 targets PTEN and PHLPP2 to augment AKT signaling and drive malignant phenotypes in non-small cell lung cancer.

Cai J, Fang L, Huang Y, Li R, Yuan J, Yang Y, Zhu X, Chen B, Wu J, Li M.

Cancer Res. 2013 Sep 1;73(17):5402-15. doi: 10.1158/0008-5472.CAN-13-0297. Epub 2013 Jul 15.

PMID:
23856247
[PubMed - indexed for MEDLINE]
12.

Response of non-small cell lung cancer cells to the inhibitors of phosphatidylinositol 3-kinase/Akt- and MAPK kinase 4/c-Jun NH2-terminal kinase pathways: an effective therapeutic strategy for lung cancer.

Lee HY, Oh SH, Suh YA, Baek JH, Papadimitrakopoulou V, Huang S, Hong WK.

Clin Cancer Res. 2005 Aug 15;11(16):6065-74.

PMID:
16115952
[PubMed - indexed for MEDLINE]
Free Article
13.

TOPK/PBK promotes cell migration via modulation of the PI3K/PTEN/AKT pathway and is associated with poor prognosis in lung cancer.

Shih MC, Chen JY, Wu YC, Jan YH, Yang BM, Lu PJ, Cheng HC, Huang MS, Yang CJ, Hsiao M, Lai JM.

Oncogene. 2012 May 10;31(19):2389-400. doi: 10.1038/onc.2011.419. Epub 2011 Sep 26.

PMID:
21996732
[PubMed - indexed for MEDLINE]
14.

Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models.

Spoerke JM, O'Brien C, Huw L, Koeppen H, Fridlyand J, Brachmann RK, Haverty PM, Pandita A, Mohan S, Sampath D, Friedman LS, Ross L, Hampton GM, Amler LC, Shames DS, Lackner MR.

Clin Cancer Res. 2012 Dec 15;18(24):6771-83. doi: 10.1158/1078-0432.CCR-12-2347. Epub 2012 Nov 7.

PMID:
23136191
[PubMed - indexed for MEDLINE]
Free Article
15.

PI3K/AKT pathway activation in bladder carcinogenesis.

Calderaro J, Rebouissou S, de Koning L, Masmoudi A, Hérault A, Dubois T, Maille P, Soyeux P, Sibony M, de la Taille A, Vordos D, Lebret T, Radvanyi F, Allory Y.

Int J Cancer. 2014 Apr 15;134(8):1776-84. doi: 10.1002/ijc.28518. Epub 2013 Oct 24.

PMID:
24122582
[PubMed - indexed for MEDLINE]
16.

A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.

Korkolopoulou P, Levidou G, Trigka EA, Prekete N, Karlou M, Thymara I, Sakellariou S, Fragkou P, Isaiadis D, Pavlopoulos P, Patsouris E, Saetta AA.

BJU Int. 2012 Dec;110(11 Pt C):E1237-48. doi: 10.1111/j.1464-410X.2012.11569.x. Epub 2012 Oct 29.

PMID:
23107319
[PubMed - indexed for MEDLINE]
17.

PIK3CA alterations in Middle Eastern ovarian cancers.

Abubaker J, Bavi P, Al-Haqawi W, Jehan Z, Munkarah A, Uddin S, Al-Kuraya KS.

Mol Cancer. 2009 Jul 28;8:51. doi: 10.1186/1476-4598-8-51.

PMID:
19638206
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Simultaneous blockade of AP-1 and phosphatidylinositol 3-kinase pathway in non-small cell lung cancer cells.

Kikuchi J, Kinoshita I, Shimizu Y, Oizumi S, Nishimura M, Birrer MJ, Dosaka-Akita H.

Br J Cancer. 2008 Dec 16;99(12):2013-9. doi: 10.1038/sj.bjc.6604782. Epub 2008 Nov 18.

PMID:
19018257
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Gefitinib (IRESSA) sensitive lung cancer cell lines show phosphorylation of Akt without ligand stimulation.

Noro R, Gemma A, Kosaihira S, Kokubo Y, Chen M, Seike M, Kataoka K, Matsuda K, Okano T, Minegishi Y, Yoshimura A, Kudoh S.

BMC Cancer. 2006 Dec 6;6:277.

PMID:
17150102
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk